Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4681 Target Snapshot

Aldo-keto reductase family 1 member C3 · SINGLE PROTEIN · Homo sapiens

1,103Compounds
190Assays
15Approved Drugs
1,383.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P42330. Use UniProt P42330 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P42330 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Aldo-keto reductase family 1 member C3 as ChEMBL target CHEMBL4681, mapped to UniProt P42330. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Aldo-keto reductase family 1 member C3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4681
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P42330
Aldo-keto reductase family 1 member C3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Aldo-keto reductase family 1 member C3 is the right protein anchor across sources, using UniProt P42330 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAldo-keto reductase family 1 member C3
UniProt AccessionP42330
Component TypeProtein
Sequence Length323 aa

Aldo-keto reductase family 1 member C3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Aldo-keto reductase family 1 member C3, mapped to UniProt P42330. Sequence length is 323 aa.

Mapped IDP42330
Review nameAldo-keto reductase family 1 member C3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

15
Approved
6
Phase III
4
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC501,319.0
KI60.0
KD4.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2413849 9.47 IC50 0.34 Preclinical
CHEMBL4110932 9.3 IC50 0.5 Preclinical
CHEMBL5821749 9.3 IC50 0.5 Preclinical
CHEMBL5823188 9.3 IC50 0.5 Preclinical
CHEMBL5830459 9.3 IC50 0.5 Preclinical
CHEMBL5780480 9.22 IC50 0.6 Preclinical
CHEMBL6057463 9.22 IC50 0.6 Preclinical
CHEMBL5861450 9.15 IC50 0.7 Preclinical
CHEMBL5937799 9.15 IC50 0.7 Preclinical
CHEMBL4113242 9.1 IC50 0.8 Preclinical
Distribution

pChEMBL Value Distribution

76
5.0
127
5.5
208
6.0
228
6.5
213
7.0
164
7.5
79
8.0
62
8.5
23
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

GLIMEPIRIDE
CHEMBL1481
Approved 1995
FLURBIPROFEN
CHEMBL563
Approved 1986
MECLOFENAMIC ACID
CHEMBL509
Approved 1980
NAPROXEN
CHEMBL154
Approved 1976
MEFENAMIC ACID
CHEMBL686
Approved 1967
INDOMETHACIN
CHEMBL6
Approved 1965
MEDROXYPROGESTERONE ACETATE
CHEMBL717
Approved 1959
Assay Landscape

Assay Landscape

190
Total Assays
993
Tested Compounds
2
Assay Types
Binding — 183 assays, 993 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 104 205 6.9
single protein format 51 447 6.3
assay format 28 341 7.2
ADME — 7 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 7 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine